ProShare Advisors LLC Purchases 2,025 Shares of Elevance Health, Inc. $ELV

ProShare Advisors LLC raised its holdings in shares of Elevance Health, Inc. (NYSE:ELV) by 5.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 42,253 shares of the company’s stock after purchasing an additional 2,025 shares during the quarter. ProShare Advisors LLC’s holdings in Elevance Health were worth $13,653,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of the business. Blair William & Co. IL grew its holdings in shares of Elevance Health by 3.0% during the second quarter. Blair William & Co. IL now owns 6,260 shares of the company’s stock valued at $2,435,000 after buying an additional 180 shares during the last quarter. IFP Advisors Inc lifted its position in Elevance Health by 6.8% in the 2nd quarter. IFP Advisors Inc now owns 704 shares of the company’s stock valued at $300,000 after acquiring an additional 45 shares in the last quarter. Trust Co. of Toledo NA OH acquired a new position in Elevance Health during the 2nd quarter valued at about $43,000. Apollon Wealth Management LLC increased its holdings in Elevance Health by 30.8% during the 2nd quarter. Apollon Wealth Management LLC now owns 3,421 shares of the company’s stock worth $1,330,000 after purchasing an additional 806 shares in the last quarter. Finally, OFI Invest Asset Management raised its stake in shares of Elevance Health by 21.8% in the second quarter. OFI Invest Asset Management now owns 235 shares of the company’s stock worth $91,000 after purchasing an additional 42 shares during the last quarter. Institutional investors and hedge funds own 89.24% of the company’s stock.

Analyst Ratings Changes

Several brokerages recently issued reports on ELV. JPMorgan Chase & Co. lifted their target price on Elevance Health from $394.00 to $397.00 and gave the company an “overweight” rating in a research report on Monday, February 2nd. Guggenheim cut their price objective on shares of Elevance Health from $414.00 to $396.00 and set a “buy” rating on the stock in a report on Thursday, January 29th. Wolfe Research set a $425.00 target price on shares of Elevance Health and gave the stock an “outperform” rating in a research note on Thursday, January 8th. TD Cowen reiterated a “buy” rating on shares of Elevance Health in a report on Wednesday, November 26th. Finally, Barclays cut their price target on shares of Elevance Health from $404.00 to $393.00 and set an “overweight” rating on the stock in a report on Friday, January 30th. Twelve investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Trading Down 0.6%

NYSE ELV opened at $325.61 on Wednesday. The stock has a market capitalization of $71.87 billion, a price-to-earnings ratio of 12.96, a PEG ratio of 1.82 and a beta of 0.50. Elevance Health, Inc. has a one year low of $273.71 and a one year high of $458.75. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.54 and a quick ratio of 1.56. The business’s fifty day moving average is $351.86 and its 200-day moving average is $331.28.

Elevance Health (NYSE:ELV) last posted its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 earnings per share for the quarter, beating the consensus estimate of $3.10 by $0.23. Elevance Health had a net margin of 2.84% and a return on equity of 15.59%. The company had revenue of $49.31 billion during the quarter, compared to analyst estimates of $49.52 billion. During the same quarter in the prior year, the business earned $3.84 earnings per share. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Equities research analysts predict that Elevance Health, Inc. will post 33.96 EPS for the current year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a dividend yield of 2.1%. The ex-dividend date is Tuesday, March 10th. This is an increase from Elevance Health’s previous quarterly dividend of $1.71. Elevance Health’s dividend payout ratio (DPR) is 27.23%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.